Literature DB >> 16308595

Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO).

C Bourgault1, Jean Davignon, George Fodor, Claude Gagné, Daniel Gaudet, Jacques Genest, Marc-Andre Lavoie, Lawrence Leiter, Ruth McPherson, Martin Sénécal, Michael Marentette, Rolf J Sebaldt.   

Abstract

BACKGROUND: Although statins are widely used to reduce low density lipoprotein cholesterol (LDL-C), there is little information about patient profiles, treatment patterns and goal achievement among statin-treated patients in Canada.
OBJECTIVES: To assess the profile of statin-treated patients and to determine whether they are achieving recommended targets for LDL-C.
METHODS: The Canadian Lipid Study -- Observational (CALIPSO) was a cross-sectional study involving Canadian physicians who were among the top statin prescribers. Each physician enrolled up to 15 patients who were at least 18 years of age with a diagnosis of hyper-cholesterolemia and who had been using a statin for at least eight weeks. Sociodemographics, coronary artery disease (CAD) risk factors, pretreatment and current lipid levels, and history of lipid-lowering therapy were reported for 3721 patients.
RESULTS: Sixty-eight per cent of statin-treated patients were at high CAD risk according to the 2003 Canadian guidelines, 46.4% had established cardiovascular disease, 33.9% had diabetes and 59.5% had hypertension. Average LDL-C reductions of 32% (37% for high-risk patients) were initially required to reach goal. At the study visit, patients had been treated for an average of 4.3 years and 24.2% were using a high statin dose. Despite statin therapy, 27.2% of all patients and 36.4% of those at high CAD risk had not achieved LDL-C targets. For 67.4% of these patients, the current therapy was not modified at the study visit.
CONCLUSIONS: Despite effective therapies, many treated patients are not achieving recommended LDL-C targets. Strategies should be implemented to promote achievement of lipid treatment goals for high-risk patients, thereby reducing the risk of cardiovascular events and their associated clinical and economic burdens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16308595

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  13 in total

1.  A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study.

Authors:  Julie Villeneuve; Jacques Genest; Lucie Blais; Marie-Claude Vanier; Diane Lamarre; Marc Fredette; Marie-Thérèse Lussier; Sylvie Perreault; Eveline Hudon; Djamal Berbiche; Lyne Lalonde
Journal:  CMAJ       Date:  2010-03-08       Impact factor: 8.262

2.  Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients.

Authors:  Soubra Lama; Domiati Souraya; Fattouh Youssef
Journal:  Int J Clin Pharm       Date:  2017-05-18

3.  Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.

Authors:  Stéphane Bissonnette; Rafik Habib; Fotini Sampalis; Stella Boukas; John S Sampalis
Journal:  Can J Cardiol       Date:  2006-10       Impact factor: 5.223

Review 4.  Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease.

Authors:  Jacques Genest
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

5.  Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study.

Authors:  Ehud Ur; Anatoly Langer; Simon W Rabkin; Cristina-Dana Calciu; Lawrence A Leiter
Journal:  Can J Cardiol       Date:  2010-02       Impact factor: 5.223

6.  Statin use in Canadians: trends, determinants and persistence.

Authors:  C Ineke Neutel; Howard Morrison; Norm R C Campbell; Margaret de Groh
Journal:  Can J Public Health       Date:  2007 Sep-Oct

7.  Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.

Authors:  M Wagner; P Lindgren; E Merikle; M Goetghebeur; B Jönsson
Journal:  Can J Cardiol       Date:  2009-11       Impact factor: 5.223

8.  Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model.

Authors:  John S Sampalis; Stéphane Bissonnette; Stella Boukas
Journal:  Adv Prev Med       Date:  2010-10-31

9.  Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial.

Authors:  A Shekhar Pandey; Stéphane Bissonnette; Stella Boukas; Emmanouil Rampakakis; John S Sampalis
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

10.  A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240].

Authors:  Finlay A McAlister; Miriam Fradette; Michelle Graham; Sumit R Majumdar; William A Ghali; Randall Williams; Ross T Tsuyuki; James McMeekin; Jeremy Grimshaw; Merril L Knudtson
Journal:  Implement Sci       Date:  2006-05-06       Impact factor: 7.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.